Stem cell developer Athersys (NASDAQ:ATHX) has secured $9 million in a private placement with an unidentified investor. Cleveland-based Athersys said it would issue about 4.3 million shares of common stock and an equal number of warrants to purchase common shares at a price of $2.07. The warrants are exercisable for five years, according to a […]
UPDATED AND CORRECTED Regenerative medicine firm Miromatrix Medical, which one day aims to grow human organs, has raised $2.05 million, according to a January letter to shareholders from CEO Robert Cohen. The two-year-old company, which counts former Republican Gov. Tim Pawlenty as a board member, has also formally launched a website. It was in Pawlenty’s […]
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
University Hospitals Case Medical Center will be one of 25 institutions in the U.S. to take part in a phase 2 clinical trial of a stem cell treatment for stroke developed by Cleveland-based Athersys (NASDAQ:ATHX). The Plain Dealer reports that MultiStem will be administered via a one-time IV infusion to 140 patients at UH and […]
Cytomedix‘s (OTC:CMXI) Aldagen acquisition signaled the company’s intention to establish a strong presence in regenerative medicine therapies and the deal fills needs for both companies. Aldagen, who had tried twice to go public only to withdraw both times amid poor market conditions, gets a partner interested in developing its stem cell treatments. Cytomedix gains prospective […]
Regenerative medicine company Cytomedix (OTC:CMXI) has acquired North Carolina stem cell technology company Aldagen in a stock deal valued at $40 million that broadens the firm’s regenerative therapies pipeline. Maryland-based Cytomedix develops biologically active regenerative therapies for wound care, inflammation and blood vessel development. The company has been diversifying to build its regenerative medicine capabilities. […]
Stem cell therapy developer Athersys (NASDAQ:ATHX) reported positive results from a phase 1 clinical trial in patients with leukemia and similar blood diseases. The trial showed that the company’s MultiStem technology may reduce the incidence and severity of graft-versus-host disease, according to a statement from Cleveland-based Athersys. Graft-versus-host disease (GvHD) often occurs after a stem […]
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
Stem cell developer Athersys (NASDAQ:ATHX) has received $3.6 million in new grant funding, with one of the grants going toward studying its MultiStem technology for the treatment of traumatic brain injury. A $1.9 million grant to study traumatic brain injury (TBI) comes from the National Institute of Neurological Disorders and Stroke, according to a statement […]
Regenerative medicine company Juventas Therapeutics is touting the results from 12-month data of a phase 1 clinical trial of heart failure patients. At 12 months, heart failure patients treated with the company’s stem cell therapy showed “significant” improvements in two key measures — a six-minute distance-walking test, as well as the Minnesota Living with Heart […]
Regenerative medicine company KeraNetics, whose biomaterials research into healing damaged tissue is already in the U.S. military’s sights, is now raising a targeted $7 million in equity financing. The Winston-Salem, North Carolina company has raised $4.7 million from 26 investors so far in a securities sale that began on Dec. 30, according to securities filings. […]
Regenerative medicine company Tengion (NASDAQ:TNGN) has relocated its headquarters from Pennsylvania to North Carolina, where the company maintains R&D operations. The move to North Carolina comes nearly two months after Tengion announced a corporate restructuring that included scaling back its Pennsylvania footprint and focusing its resources on the R&D facility in Winston-Salem, North Carolina. The […]
The TSX Venture Exchange has a strong history of helping early-stage health and life sciences companies raise patient capital for research and development.
Athersys (NASDAQ:ATHX) has obtained a U.S. patent that covers the use of nonembryonic multi-potent stem cells for the treatment of several heart conditions, including heart attack. The patent provides protection for “multiple techniques” for delivering the stem cells to treat the conditions, which also include congestive heart failure and myocardial ischemia, according to a statement […]
John L. Miclot has been appointed CEO of Tengion (NASDAQ:TNGN), a regenerative medicine business in East Norriton, Pennsylvania, as it pursues strategic partnership discussions. Miclot fills a vacancy left by Steven A. Nichtberger who resigned in June. David I Scheer, chairman of Tengion’s board, had taken a more active role in the company until a […]
Regenerative medicine company Tengion (NASDAQ:TNGN) is restructuring with moves that reduce headcount, focus operations on its North Carolina R&D arm and conserve enough cash to last another year. Tengion said the restructuring plan will allow the company to fund its lead development programs through key milestones next year while also cutting its spending. The company […]
Current medical news from today, including a milestone in regenerative medicine as the first umbilical cord blood is approved for use in stem cell transplantation, scientists develop a blood glucose sensor that uses tears, and China's largest biotech goes public.
Current medical news from today, including success and setbacks in embryonic stem cell research with Parkinson's and diabetes, Johnson & Johnson's rivaroxaban approved for stroke prevention in atrial fibrillation patients, and venture capital in healthcare.